SCHEMBL9914904

SCHEMBL9914904

O=C(C(=O)N1CCN(C(=O)C2CCCO2)CC1)c1c[nH]c2c(-n3ccnn3)ncc(F)c12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HTT P42858 1/20 0.40
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
PARP1 P09874 3/20 0.34
LMNA P02545 2/20 0.34
POLB P06746 1/20 0.34
GLA P06280 1/20 0.34
CNR2 P34972 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15273565 0.87 CYP3A4 (0.39) ALDH1A1TSHRCYP3A4CYP1A2CYP2C8
SCHEMBL9914932 0.87 CYP3A4 (0.39) CYP3A4CYP1A2CYP2C8CYP2D6CYP2C9
SCHEMBL9914929 0.87 CYP3A4 (0.40) CYP3A4CYP1A2CYP2C8CYP2D6CYP2C9
SCHEMBL9914940 0.87 CYP3A4 (0.37) ALDH1A1KDM4ECYP3A4CYP1A2CYP2C8
SCHEMBL9914941 0.87 CYP3A4 (0.37) ALDH1A1KDM4EHSD17B10HTTCYP3A4
SCHEMBL9914912 0.86 CYP3A4 (0.38) ALDH1A1TSHRCYP3A4CYP1A2CYP2C8
SCHEMBL9914942 0.86 CYP3A4 (0.38) ALDH1A1TSHRCYP3A4CYP1A2CYP2C8
SCHEMBL9914937 0.85 CYP3A4 (0.38) CYP3A4CYP1A2CYP2C8CYP2D6CYP2C9
SCHEMBL15273600 0.84 CYP3A4 (0.37) CYP3A4CYP1A2CYP2C8CYP2D6CYP2C9
SCHEMBL9914919 0.84 CYP3A4 (0.38) CYP3A4CYP1A2CYP2C8CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2646439-B1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-05-25 EP disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-8912195-B2 Alkyl amides as HIV attachment inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-12-16 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2013-09-26 US disclosed
WO-2012075235-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252968-A1 ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS NAPA, ASNS, CD4 ALDH1A1 542/4885KDM4E 689/4885TSHR 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.